Antitachycardia pacing success in implantable cardioverter-defibrillators by patient, device, and programming characteristics
Heart Rhythm, ISSN: 1547-5271, Vol: 20, Issue: 2, Page: 190-197
2023
- 7Citations
- 12Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations7
- Citation Indexes7
- CrossRef5
- Captures12
- Readers12
- 12
Article Description
Antitachycardia pacing (ATP) is an established implantable cardioverter-defibrillator (ICD) therapy that terminates ventricular tachycardias (VTs) without painful ICD shocks. However, factors influencing ATP success are not well understood. The purpose of this study was to examine ATP success rates by patient, device, and programming characteristics. This retrospective analysis of the PainFree SmartShock Technology study included spontaneous ATP-treated monomorphic VT episodes. ATP success rates were calculated for various factors. Also, the relationship of ATP programming on shock burden and syncope were investigated. Of the 2770 enrolled patients (2200 [79%] male; mean age 65 years), 1699 (61%) received an ICD and 1071 (39%) a cardiac resynchronization therapy – defibrillator. ATP had >80% rate of success for terminating VTs overall, with similar rates observed between ICD and cardiac resynchronization therapy – defibrillator devices (82.2% vs 80.3%, respectively; P =.81) as well as between primary and secondary prevention patients with ICDs (77.2% vs 83.9% respectively; P =.25). Arrhythmias with a median cycle length of ≥320 ms had a significantly higher ATP success rate (88.0%; 95% confidence interval 84.8%–90.6%). The cumulative percentage of ATP success increased from 71% at 1 ATP sequence delivered to 87% at ≥8 sequences delivered. Programming more ATP sequences was associated with lower shock burden ( P =.0005). There was no evidence that more sequences were associated with higher rates of syncope ( P =.16). Delivering more ATP sequences resulted in a higher overall success of terminating VTs, while programming more ATP was associated with decreased shock burden and no evidence of increased syncope or acceleration. This suggests that more ATP sequences should be programmed when possible, but confirmation in prospective studies will be necessary.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1547527122025176; http://dx.doi.org/10.1016/j.hrthm.2022.10.015; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85142494421&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/36272710; https://linkinghub.elsevier.com/retrieve/pii/S1547527122025176; https://dx.doi.org/10.1016/j.hrthm.2022.10.015
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know